Non-resecable Metastatic Cancer of the Pancreas, Non-resectable Metastatic Cancer of Gastrointestinal Neuroendocrine Tumour, Non-resectable Metastatic Cancer of the Bile Duct, Non-resectable Metastatic Cancer of the Colon, Non-resectable Metastatic Cancer of the Lung, Non-resectable Metastatic Cancer of the Rectosigmoid Junction, Non-resectable Metastatic Cancer of the Rectum, Non-resectable Metastatic Cancer of the Stomach
Conditions
Brief summary
Reflexion on the therapeutic strategies to implement in patients at the end of life is advancing rapidly in France. However, beyond the choices presented to patients, sometimes even the decision to carry on, to limit or to stop treatments is also questioned. This decision is subjective; it is influenced by the patient's representation system (emotions, beliefs, values, practices, etc). In addition, even though he or she is the focus of the decision, the patient is not alone; other actors, accompanying the patient, play an important role in the final decision making. These actors, namely the doctors and close relatives, are also influenced in their decision making. This coexistence of representation systems may interfere with objective indicators that help in decision making (functional, clinical and biological) or with the knowledge acquired by doctors in their training and may complicate the decision-making process.
Interventions
OTHERInterviews
Semi-directed interviews, recorded and transcribed for analysis
OTHERQuestionnaires
economic and psycho-social questionnaires
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
I- PATIENTS * men or women * who have been informed about the study * and who have provided verbal consent to take part in the study * able to understand written and spoken French * with non-resectable metastatic cancer of: the colon, or the rectosigmoid junction or the stomach or bile ducts or rectum or gastrointestinal neuroendocrine tumor or lung (not small-cell cancer) or pancreas * with a caregiver designated as the principal caregiver (family, friend, neighbour) * who has consented to the principal caregiver taking part in a qualitative interview * able to take part in an interview lasting roughly one hour II- CAREGIVERS * men or women * who have been informed about the study * who have provided verbal consent to take part in the study * able to understand written and spoken French * able to follow an interview lasting roughly one hour III-DOCTORS * men or women * who have been informed about the study * who have provided verbal consent to take part in the study * specialised in specific organ or oncologist prescriber
Exclusion criteria
I- PATIENTS * under guardianship or ward of court * with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis, severe mental retardation etc.) II- CAREGIVERS * under guardianship or ward of court, * with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis…), * with severe mental retardation impairing ability to understand.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of determinants which are privileged by the patients to choose a treatment | through study completion, an average of 18 months |
| Type of determinants which are privileged by the patients to choose a treatment | through study completion, an average of 18 months |
Countries
France
Outcome results
None listed